Agreements - Summary of Total Purchase Price Allocated to Acquired Assets (Detail) - U.S. Rights for FYCOMPA [Member] $ in Thousands |
1 Months Ended |
|---|---|
|
Jan. 31, 2023
USD ($)
| |
| Asset Acquisition [Line Items] | |
| Inventory | $ 4,100 |
| Prepaid expenses and other current assets (samples) | 130 |
| Prepaid commercialization expenses | 1,576 |
| Property and equipment, net | 433 |
| License and acquired intangibles for FYCOMPA® | 158,143 |
| Accrued preclinical and clinical trial expenses | (174) |
| Total purchase consideration | $ 164,208 |
| X | ||||||||||
- Definition Asset acquisition, accrued preclinical and clinical trial expenses. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition, inventory current. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition, license and acquired intangibles for FYCOMPA®. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition,, prepaid expenses and other current assets. No definition available.
|
| X | ||||||||||
- Definition Asset acquisition, property and equipment, net. No definition available.
|
| X | ||||||||||
- Definition Asset acquistion, prepaid commercialization fees. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|